Identification of fluorescence in situ hybridization assay markers for prediction of disease progression in prostate cancer patients on active surveillance

Katerina Pestova\(^1\)*, Adam J. Koch\(^1\), Charles P. Quesenberry\(^1,2,3\), Jun Shan\(^3\), Ying Zhang\(^1\), Amethyst D. Leimpeter\(^3\), Beth Blondin\(^1\), Svetlana Sitalo\(^1\), Lela Buckingham\(^2\), Jing Du\(^1\), Huixin Fei\(^1\) and Stephen K. Van Den Eeden\(^3\)

Abstract

Background: Prostate Cancer (PCa) is the second most prevalent cancer among U.S. males. In recent decades many men with low risk PCa have been over diagnosed and over treated. Given significant co-morbidities associated with definitive treatments, maximizing patient quality of life while recognizing early signs of aggressive disease is essential. There remains a need to better stratify newly diagnosed men according to the risk of disease progression, identifying, with high sensitivity and specificity, candidates for active surveillance versus intervention therapy. The objective of this study was to select fluorescence in situ hybridization (FISH) panels that differentiate non-progressive from progressive disease in patients with low and intermediate risk PCa.

Methods: We performed a retrospective case-control study to evaluate FISH biomarkers on specimens from PCa patients with clinically localised disease (T1c-T2c) enrolled in Watchful waiting (WW)/Active Surveillance (AS). The patients were classified into cases (progressed to clinical intervention within 10 years), and controls (did not progress in 10 years). Receiver Operating Characteristic (ROC) curve analysis was performed to identify the best 3–5 probe combinations. FISH parameters were then combined with the clinical parameters — National Comprehensive Cancer Network (NCCN) risk categories — in the logistic regression model.

Results: Seven combinations of FISH parameters with the highest sensitivity and specificity for discriminating cases from controls were selected based on the ROC curve analysis. In the logistic regression model, these combinations contributed significantly to the prediction of PCa outcome. The combination of NCCN risk categories and FISH was additive to the clinical parameters or FISH alone in the final model, with odds ratios of 5.1 to 7.0 for the likelihood of the FISH-positive patients in the intended population to develop disease progression, as compared to the FISH-negative group.

Conclusions: Combinations of FISH parameters discriminating progressive from non-progressive PCa were selected based on ROC curve analysis. The combination of clinical parameters and FISH outperformed clinical parameters alone, and was complimentary to clinical parameters in the final model, demonstrating potential utility of multi-colour FISH panels as an auxiliary tool for PCa risk stratification. Further studies with larger cohorts are planned to confirm these findings.

Keywords: Prostate cancer, Genomic abnormalities, Prognosis, Risk stratification, FISH, Fluorescence in situ hybridisation, Biopsy

* Correspondence: ekaterina.pestova@abbott.com

\(^1\)Abbott Molecular, Inc., 1300 East Touhy Avenue, Des Plaines, IL 60018, USA

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Prostate cancer (PCa) is the second most common cancer in men with approximately 161,360 men diagnosed annually in the US [1] and 1.1 million men worldwide [2]. Although the lifetime risk of developing PCa is approximately 1 in 6 (~16%), the risk of dying from the disease is only ~2% [3]. Early diagnosis and treatment improved survival in patients with high-risk cancers, however, concerns exist regarding over diagnosis and over treatment of men with lower-risk PCa due to comorbidities and healthcare costs [4, 5]. Over the last 15–20 years, what was the watchful waiting (WW) approach has evolved into active surveillance (AS), and has gained popularity for managing lower-risk PCa [4, 6, 7]. Men on AS are monitored with periodic biopsies, prostate examination, and prostate-specific antigen (PSA) tests, and treated only when the PCa shows signs of progression.

Clinical parameters such as Gleason score, PSA levels, patient demographics, and combinations of these parameters are used to stratify patients with low-risk (indolent) prostate cancer for AS. Novel imaging and molecular diagnostic tools are emerging to aid in patient risk stratification and monitoring on AS [7–9]. New genomic biomarkers and biomarker panels, including gene copy number, rearrangements and germline mutations, are being assessed for association with clinically and histologically aggressive disease [10–12]. However, current methods still lack the precision needed to reliably discriminate men with varying PCa risks. Given that PCa is both a biologically and clinically heterogeneous disease that develops amidst diverse genetic and epigenetic changes [13–15], identification of molecular biomarkers that can reliably discriminate aggressive vs indolent disease, as well as biomarkers for monitoring of progression during AS is paramount.

Fluorescence in situ hybridisation represents a widely-used molecular technique that allows the detection of numerical and structural abnormalities in tissue and cytology specimens. Multiple chromosomal alterations have been reported in PCa, such as chromosome aneuploidy, gain of the 8q24 (MYC) region, loss of 10q23 (PTEN) region, and translocations of ERG and ETV1 genes [13, 16–22].

In this study, we evaluated FISH biomarkers on a retrospective case-control cohort of 108 PCa patients on WW/AS in order to establish a panel that can differentiate non-aggressive prostate cancer from aggressive prostate cancer.

Methods
FISH probes
A total of 12 probes including 2 centromeric probes (CEP™) and 8 locus-specific identifiers (LSI™) were used. All probes were obtained from Abbott Molecular, Inc. (Des Plaines, IL). The probes were assembled in three four-color hybridisation probe mixes. Probe mix 1, consisted of SpectrumGold™ PTEN (10q23), SpectrumAqua™ CEP10 (10p11.1-q11.1), and a Dual Colour ERG Break-Apart probe containing SpectrumRed™ ERG Cen (21q22) and SpectrumGreen™ ERG Tel (21q22). Probe mix 2 included SpectrumGold™ NXX3.1 (8p21), SpectrumAqua™ CEP8 (8p11.1-q11.1), SpectrumRed™ FGFR1 (8p12) and SpectrumGreen™ MYC (8q24). Probe mix 3 contained SpectrumGold™ CDKN1B (9p21), SpectrumAqua™ NMYC (2p24), and the Dual Colour ETV1 Break-Apart probe containing SpectrumGreen™ ETV1 Cen (7p21) and SpectrumRed™ ETV1 Tel (7p21) probes. Additional probes, SpectrumAqua™ MDM2 (20q13.2) and SpectrumRed™ AURKA (20q13.2) were used in the initial feasibility study.

Initial feasibility study on radical prostatectomy specimens
Fifty-two archived, formalin-fixed paraffin embedded (FFPE) radical prostatectomy (RP) specimens from patients with adenocarcinoma of prostate were collected at Rush Medical Center (RUMC), Chicago, IL. The specimen set included 10 patients with Gleason score of <6, 14 patients with Gleason score of 6, 19 patients with Gleason score of 7, and 9 patients with Gleason score of 8 and 9. Patient age ranged from 46 to 76 years old, with a median age of 62. The specimens were collected during the period from 1990 to 2012, with a follow up time of 4–15 years, with a median follow up time of 12.5 years. Thirty-two of the 52 patients recurred within 5 years (PSA progression or death of disease), and 20 remained disease-free with 8 to 15 years.

Developmental study on prostate biopsy specimens
To further develop the assay, a study was conducted on core needle biopsy specimens collected by Kaiser Permanente Northern California (KPNC). The nested case-control included men with local stage prostate cancer who were classified as Very Low, Low or Intermediate risk disease, who had a diagnostic PSA level of 10 or under and a biopsy Gleason score of 7 or under and were part of an active surveillance program. “Cases” were men diagnosed with localised prostate cancer who had definitive evidence of disease progression within 10 years of diagnosis of prostate cancer. “Controls” were individuals matched to cases on age (±10 years), disease stage and grade, PSA level, age, race, and dates of diagnosis and follow-up. Summary of primary clinical characteristics for cases and controls is provided in the Additional file 1. One hundred eighteen de-identified, blinded Formalin-Fixed Paraffin-Embedded (FFPE) tumour samples were received from the KPNC Biospecimen repository. The specimens were from the initial
diagnostic biopsy, collected from 1997 to 2003. Each case had a minimum of 6 cores.

Specimens were from patients that either (1) have a minimum of 10 years follow-up data and did not show disease progression, or (2) had progression of disease within 10 years of diagnosis. Median follow up time for the patients on study was 13 years (11 years for the 41 patients who died, and 14 years for those patients who were alive at the time of the study initiation). Progressive disease was defined as showing progression to metastases confirmed by imaging or as three consecutive rises in PSA level during surveillance leading to definitive therapy. Of the patients with progressive disease, 25% progressed within 1 year, 50% progressed within 1 to 3 years, and 25% had a progression time of greater than 3 years.

The FFPE blocks were sectioned into a minimum of five 5-micron sections and applied to positively-charged microscope slides. The specimens were characterised by staining one out of 5–10 serial sections with haematoxylin and eosin (H&E) followed by examination by an expert pathologist at a central laboratory to mark (scribe) the tumour area and to assign Gleason scores following current grading criteria. The specimen slides used for the FISH assay procedure were within 10 serial sections of the respective H&E-stained slide to assure minimal separation of the areas examined by FISH from the areas evaluated by histopathology.

**Histological sample pretreatment and hybridisation**

FFPE histological specimen slides were baked at 56 °C for 2–24 h and treated three times in Hemo-De (Scientific Safety Solvents) for 5 min each at room temperature, followed by two 1-min rinses in 100% ethanol at room temperature. Slides were then pretreated using Vysis IntelliFISH Universal FFPE Tissue Pretreatment and Wash Reagents as follows. Slides were incubated in pretreatment solution at 80 °C for 35 min, rinsed for 3 min in deionised water, incubated 10–20 min in 0.15% pepsin in 0.1 N HCl solution at 37 °C, and rinsed again for 3 min in deionized water. Slides then were dehydrated for 1 min each in 70, 85, and 100% ethanol and air-dried. Batch processing of slides was carried out in the VP 2000 Slide Processor (Abbott Molecular). After pretreatment, three slides from each specimen were hybridised with three hybridisation probe mixes containing FISH probes combined with blocking DNAs and LSI/WCP Hybridisation Buffer (Abbott Molecular, Inc., Des Plaines, IL). Ten microliters of each hybridisation probe mix were added to a specimen, a coverslip was applied and sealed with rubber cement. Slides and probes were co-denatured for 5 min at 73 °C and hybridised for 16–24 h at 37 °C on a ThermoBrite Hybridisation System (Abbott Molecular, Inc.). After hybridisation, coverslips were removed by soaking the slides in 2X SSC/0.3% NP-40 for 2–5 min at room temperature, followed by a wash in 2X SSC/0.3% NP-40 at 73 °C for 2 min. The slides were then allowed to dry in the dark. Ten microliters of 4’,6-diamidino-2-phenylindole counterstain/antifade solution (DAPI I, Abbott Molecular, Des Plaines, IL) was added to the specimen, and a coverslip was placed on the slide prior to evaluation.

**FISH signal evaluation**

The specimens were analysed using a fluorescence microscope equipped with single bandpass filters (Abbott Molecular, Des Plaines, IL) specific for DAPI, Spectrum Gold™, SpectrumRed™, SpectrumGreen™, and Spectrum Aqua™. In addition, a dual bandpass Red/Green filter was used to evaluate break-apart ERG and ETV1 probes. For each specimen, 100 consecutive non-overlapped, intact interphase nuclei within the scribed area were enumerated.

**Statistical analysis**

The following FISH parameters were calculated for the abnormal patterns of each probe, based on signal enumeration results:

- “Gain” percent cells with >2 signals;
- “Loss”, percent cells with <2 signals;
- “Homozygous” deletion – percent of cells with 0 FISH signals for a probe;
- “Ratio” – ratio of the average number of probe signals per cell to the average number of signals for the CEP control probe located on the same chromosome;
- “Split” – for a break-apart probe, green and red signals separated by a distance of ≥1 signal width: translocation detected;
- “2Edel” – for the ERG break-apart probe: separated green and red signals associated with the gain or amplification of single red signals and the concurrent loss of at least one of the green signals [23].

For the initial feasibility study, candidate probes and multicolour probe combinations were prioritised using ROC analysis and the Cox Proportional Hazards model, using disease recurrence or death from disease within the follow up period of 15 years (progression) as the outcome.

For the developmental study on the prostate biopsy specimens, “Cases” were designated as those patients who did not receive any curative treatment within 1 year of diagnosis but were classified as having progressive prostate cancer within 10 years of diagnosis, and “Controls” as those who did not receive curative or palliative treatment within 10 years of diagnosis and did not have evidence of progressive prostate cancer. The
receiver operating characteristic (ROC) method [24] and correlation analysis were used to select and prioritise individual candidate FISH parameters. Individual FISH parameters were grouped in combinations, and the ROC method was used to (i) select optimal FISH parameter combinations by calculating and comparing the Area Under the Curve (AUC); (ii) select the optimal cut-off value for individual FISH probes by calculating and comparing the Distance From Ideal (DFI). AUC was used as the criterion for selecting the optimal FISH parameter combinations in respect to their ability to distinguish progressive (Case) vs. non-progressive disease (Control).

For each FISH parameter, cut-offs were established in a combinatorial analysis based on percentage of cells containing a genomic abnormality. Each cut-off was determined by simulating all possible cut-off combinations (for each parameter in the parameter combination), and choosing those cut-offs for each parameter that resulted in the lowest DFI for the parameter combination which provided both highest sensitivity and specificity. DFI is defined as $\sqrt{\left(1-\text{sensitivity}\right)^2 + \left(1-\text{specificity}\right)^2}$. DFI represents the minimum distance from the ROC curve to the value of a sensitivity of 1 and a false positive rate (1-specificity) of 0. The DFI ranges from 0 to 1, with 0 being the ideal. In this analysis, FISH positivity and negativity was assigned based on the cut-off values, such that if any of the FISH parameters in the combination was greater than or equal to the cut-off, the specimen was considered positive, while if all FISH parameters in the combination were below the cut-off, the specimen was considered negative.

To evaluate the strength of the association between FISH parameters, clinical parameters and the progressive PCa, a logistic regression analysis was performed by using the selected probe sets and NCCN Prostate Cancer Risk Groups (“NCCN Risk Groups”). The Risk Groups are based on tumour stage, PSA, Gleason score and metastatic status and include Very Low, Low, Intermediate, High, Very High and Metastatic groups [25]. In this regression analysis, FISH parameters were treated as categorical variables based on optimal cut-offs from the AUC analysis. To determine if there was any significant correlation between individual FISH biomarker and the clinical parameters, Pearson’s correlation coefficients were calculated. A $p$-value less than 0.05 was considered to be statistically significant.

All analyses were performed using SAS version 9.2 or above (SAS Institute Inc., Cary, NC, USA.) by Abbott Molecular Biostatistics and Data Management Group.

**Results**

**Initial feasibility – probe selection on radical prostatectomy specimens**

FISH probes for this study were chosen based on the initial feasibility of multi-colour FISH on 52 formalin-fixed paraffin embedded RP specimens from patients with adenocarcinoma of prostate, collected at Rush Medical Center (RUMC), Chicago, IL. In the initial feasibility study, specimens were tested with 14 FISH probes: PTEN (10q23), NKX3.1 (8p21), CDKN1B (9p21), CEP10 (10p11.1-q11.1), MYC (8q24), AURKA (20q13.2), ERG Cen (21q22), ERG Tel (21q22), ETVI Tel (7p21), ETVI Cen (7p21), MD2M (12q14-15), NMYC (2p24), FGFR1 (8p12), and CEP8 (8p11.1-q11.1). Candidate probes and multicolour probe combinations were prioritised using ROC analysis and Cox Proportional Hazards model, using disease recurrence or death of disease (DOD) within the follow up period of 15 years as the outcome. Analysis of probes and probe combinations demonstrated that grouping of complimentary biomarkers was needed to achieve maximum performance, and that combinations could be selected with the potential to predict longer progression free time for FISH test negative patients. Specifically, patients positive for either FISH parameter in the combination, had more risk of developing progression comparing to patients in the FISH (−) group with a Hazard Ratio (HR) of 4.65. Based on the initial feasibility study, probes that did not demonstrate prognostic value either alone, or in combinations, were eliminated, resulting in selection of the following probes for further testing on the prostate biopsy specimens from the AS cohort: PTEN, CEP10, ERG Cen, ERG Tel, NKX3.1, CEP8, FGFR1, MYC, CDKN1B, NMYC, ETVI Cen and ETVI Tel.

**Detection of cytogenetic abnormalities by FISH in prostate biopsy specimens**

A total of 118 specimens from KPNC with tumour area marked by a pathologist were pretreated and hybridised with each of the 3 multi-colour FISH probe sets. Of these specimens, 108 resulted in successful hybridisation (Fig. 1). The unsuccessful specimens did not withstand tissue pretreatment and the hybridisation process, demonstrated cell loss and lack of fluorescent signal, and could not be recovered with conventional troubleshooting methods. The reason for failures is likely attributable to the condition of a given specimen and variability in tissue fixation methods in the archived specimens.

No significant aneuploidy was observed in the specimens overall, with average copy numbers for the centromere probes CEP 8 and CEP 10 of 1.84 and 1.87, respectively. The value of less than 2 reflects typical truncation artefacts in FFPE tissue sections, and is expected. There was a slight increase in average copy number for CEP 8 and CEP 10 in cases as compared to controls (1.91 vs 1.80 for CEP 8 and 1.93 vs 1.82 for CEP 10).

Upon signal enumeration for each probe, mean percent cells with FISH abnormalities (gain, loss,
homozygous loss, homozygous loss, split and 2Edel) per specimen was compared between cases (progressive disease) and controls (non-progressive disease). Correlation analysis between FISH parameters and clinical parameters (age, Gleason score and PSA) indicated that the only statistically significant correlation observed was for the NKX3.1 probe. The NKX3.1 Loss parameter had a statistically significant correlation with the Gleason score, while NKX3.1 Ratio parameter had a significant correlation with the tumour stage (Additional file 2). Based on this observation, NKX3.1 was excluded from further analysis.

Selection of optimal probe combinations
Logistic regression — ROC curve analysis — was conducted to prioritise individual FISH parameters derived from signal enumeration with respect to their ability to distinguish progressive vs non-progressive disease, as described in the Methods section. Seven parameters (PTEN Homozygous, MYC gain, FGFR1 Gain, NMYC Gain, ETV1 Split, PTEN Loss and ERG 2Edel) were selected (Additional file 1) and then grouped in all possible combinations of 3–6 parameters. ROC curve analysis was performed on these combinations of parameters to identify combinations that can discriminate cases — those who progressed within 10 years (sensitivity) vs controls — those who did not progress within 10 years (specificity), with maximum sensitivity and specificity as judged by the AUC and DFI. Cut-off values for each probe were selected in this analysis. The optimal cut-offs expressed as percent of cells with an abnormality were in the ranges of 2–15 for amplification probes, 10–20 for deletion probes, and 4–10 for break apart probes. Parameter combinations with the highest AUC are shown in Table 1. The individual FISH parameters were not included since they were inferior to the combinations. Since both 2Edel and ETV1 Split parameters rely on 2 FISH probes, the probe combinations presented in Table 1 require 3–6 FISH probes. Interestingly, increasing the number of parameters from 4 to 5 did not appear to increase the AUC.

Performance of FISH with clinical parameters in the logistic regression model
Logistic regression analysis using proposed cut-offs demonstrated that the selected parameter combinations

![Example Images of Abnormal FISH Signals in Prostate Biopsy Tissue.](image)

**Table 1** Selected 3, 4 and 5-parameter combinations with the lowest DFI and the highest AUC.

| # Probes | FISH Parameter 1          | FISH Parameter 2          | FISH Parameter 3          | FISH Parameter 4 | FISH Parameter 5   | FISH Parameter 6 | AUC | DFI (Minimum) |
|---------|---------------------------|---------------------------|---------------------------|------------------|-------------------|------------------|-----|--------------|
| 3       | MYC Gain                  | PTEN Homozygous           | FGFR1 Gain                |                  |                   |                  | 0.71 | 0.43         |
| 3       | MYC Gain                  | PTEN Homozygous           | NMYC Gain                 |                  |                   |                  | 0.73 | 0.43         |
| 4       | MYC Gain                  | PTEN Homozygous           | NMYC Gain                 | FGFR1 Gain       |                   |                  | 0.73 | 0.45         |
| 4       | MYC Gain                  | PTEN Homozygous           | FGFR1 Gain                |                  |                   |                  | 0.72 | 0.41         |
| 5       | MYC Gain                  | PTEN Homozygous           | NMYC Gain                 | ERG 2Edel        |                   |                  | 0.73 | 0.45         |
| 5       | MYC Gain                  | PTEN Homozygous           | NMYC Gain                 |                  | ERG 2Edel         |                  | 0.72 | 0.42         |
| 6       | MYC Gain                  | PTEN Homozygous           | NMYC Gain                 | FGFR1 Gain       | ERG 2Edel         |                  | 0.73 | 0.46         |
were significant in stratifying cases from controls. In the logistic regression analysis, FISH had a significant contribution to the prediction of PCa outcome (progression) with the highest Odds Ratio (OR) of 7.005 observed for the combination of 5 probes (4 parameters), as shown in Table 2. FISH parameters were independent of clinical parameters in the model.

Clinical information was available to apply NCCN risk stratification criteria for 107 out of 108 patients in this study. Out of 107 patients, 24 were classified as High risk, 29 were classified as Intermediate risk, and 54 as Low and Very Low risk by these criteria. To assess whether FISH could be additive to risk stratification using NCCN criteria, risk groups based on clinical parameters were added to the regression model. According to Table 2, the combination of clinical parameters and FISH outperformed FISH alone for all FISH probe combinations: the OR for FISH was stronger when adjusted for risk group, as compared to unadjusted. We would like to note that in our analysis, patient age did not prove to be significant in either of the logistic regression models. Combination of clinical parameters with FISH resulted in Odds Ratios of 5.1–7.0. Therefore, those patients who are risk-stratified according to NCCN guidelines and who are also FISH positive appear to be seven times more likely to develop progression than those who are FISH-negative. For comparison, in the logistic regression analysis model that included only clinical parameters without FISH, the Odds Ratios were calculated to be 3.690 and 0.965 for NCCN Risk Groups and age, respectively. Additionally, both clinical parameters and FISH predictor variables were significant in this model. Thus, FISH appears to be additive in its predictive value to clinical parameters.

To assess predictive power of FISH with respect to disease progression by risk category, the patients were stratified in 3 categories: lower risk (including Low and Very Low risk NCCN groups), intermediate risk (Intermediate risk NCCN group), and higher risk (High risk NCCN group), and logistic regression analysis was performed on each group for FISH combinations (Table 3). Although sample size was relatively low in this study, FISH was statistically significant in discrimination of progressive vs non-progressive disease in lower and intermediate risk categories. In this analysis, the highest OR was observed in the intermediate risk category.

**Discussion**

The natural history of prostate carcinoma is highly variable, and it can be difficult, using current methodologies, to distinguish between patients with aggressive PCa that causes rapid tumour progression and significant clinical outcomes, and patients with indolent PCa. [26]. Undiagnosed, primarily indolent, prostate cancer is a common incidental finding in elderly men at autopsy [27]. This has important implications for management of PCa patients. Prostate specific antigen screening, for example, allows detection of more cases of asymptomatic prostate cancer, however, some of these tumours may not be biologically malignant. Patients with such indolent tumours would have little benefit from medical intervention, in part due to the comorbidities resulting from intervention therapy, such as radical prostatectomy (RP), which remains a preferred option for treatment of apparently localised disease. Thus, overtreatment of low-risk prostate cancer, which still occurs frequently, has significant impact on patient quality of life and health-related costs [28]. Radical prostatectomy represents a worthwhile medical intervention for patients cured of a life-threatening disease, however, not for patients whose tumours are not biologically aggressive, or for those patients who are discovered to have metastases a few months after surgery. This highlights the necessity for discovery and validation of reliable molecular markers to predict the behaviour of individual carcinomas.

FISH is an established molecular platform widely used in single, dual, or multicolour format for the detection of numerical and structural genomic abnormalities [29, 30]. The advantage of multicolour FISH is that this relatively simple technique allows for assessment of several genomic markers simultaneously in the context of the tissue specimen, capturing both genomic and structural heterogeneity of the prostate cancer. With the advent of automation and imaging systems, as well as assay chemistry improvements to reduce time to result, multiplex detection of more than four colours on one tissue specimen slide in 1–2 days has become possible [30, 31].

This study assessed whether multicolour FISH could be used to predict progressive PCa. In the preliminary feasibility, radical prostatectomy specimens were used to select FISH probes capable of discriminating patients who would recur within a 15-year follow-up period from those who would not. The hypothesis was that the disease recurrence in radical prostatectomy patients may reflect an aggressive form of prostate adenocarcinoma, with underlying molecular mechanisms that may overlap with those that enhance disease progression in patients on active surveillance. Based on the feasibility results, 12 probes were selected with a potential to discriminate progressive disease. These probes were organised in 3 probe sets and tested on core needle biopsy specimens obtained from patients who were enrolled in Active Surveillance and had a minimum of 10 years follow-up data. FISH evaluation parameters were derived from enumeration results for each probe, and individual parameters, as well as parameter combinations, were analysed to identify the best combinations capable of discriminating progressive from indolent disease in the AS cohort.
Table 2 Logistic Regression Models of FISH Only and FISH with Clinical Parameters (NCCN Risk Groups). Odds ratios, the corresponding confidence limits (CL) and p values are provided for both predictor variables (FISH and NCCN Risk Groups, respectively) in the second model. If any of the FISH parameters in the combination is greater than or equal to the cut-off, the specimen is considered positive; if all FISH parameters in the combination are below the cut-off, the specimen is considered negative

| FISH Parameter Combination | n Cases | n Controls | FISH Only Model | FISH With Clinical Parameters Model | NCCN Risk Groups |
|---------------------------|---------|------------|----------------|-----------------------------------|-----------------|
|                           |         |            | Odds Ratio  | 95% Wald Lower CL | 95% Wald Upper CL | p Value | Odds Ratio  | 95% Wald Lower CL | 95% Wald Upper CL | p Value |
| MYC Gain & FGFR1 Gain & PTEN Homozygous | 58      | 49         | 5.125      | 2.288            | 13.308             | 0.0001 | 6.221      | 2.441            | 15.851             | 0.0001 |
| MYC Gain & PTEN Homozygous & NMYC Gain | 61      | 46         | 5.631      | 2.343            | 14.248             | 0.0001 | 5.889      | 2.299            | 15.084             | 0.0002 |
| MYC Gain & PTEN Homozygous & NMYC Gain & FGFR1 Gain | 55      | 52         | 5.647      | 2.395            | 12.583             | <0.0001 | 7.005      | 2.835            | 17.306             | <0.0001 |
| MYC Gain & PTEN Homozygous & ETV1 Split | 58      | 49         | 6.125      | 2.657            | 14.119             | <0.0001 | 6.402      | 2.666            | 15.374             | <0.0001 |
| MYC Gain & PTEN Homozygous & NMYC Gain & 2 Edel | 62      | 45         | 5.173      | 2.343            | 14.248             | 0.0001 | 5.889      | 2.299            | 15.084             | 0.0002 |
| MYC Gain & PTEN Homozygous & NMYC Gain & ETV1 Split | 62      | 45         | 6.205      | 2.616            | 16.831             | <0.0001 | 6.431      | 2.463            | 16.789             | <0.0001 |
| MYC Gain & PTEN Homozygous & NMYC Gain & FGFR1 Gain & 2 Edel | 63      | 44         | 4.761      | 2.015            | 10.533             | 0.0003 | 5.065      | 2.110            | 12.160             | 0.0003 |

Pestova et al. BMC Cancer (2018) 18:2
### Table 3: Logistic Analysis of FISH Marker Combinations by Risk Category

| FISH Parameter Combination                  | Lower Risk | Intermediate Risk | Higher Risk |
|---------------------------------------------|------------|-------------------|-------------|
|                                            | n Cases    | n Controls        | Odds Ratio  | p Value  |
| MYC Gain & FGF1 Gain & PTEN Homozygous     | 29         | 25                | 6.017       | 0.0033   |
| MYC Gain & PTEN Homozygous & NMYC Gain     | 29         | 25                | 6.017       | 0.0033   |
| MYC Gain & PTEN Homozygous & NMYC Gain & FGF1 Gain | 28   | 26                | 4.886       | 0.0074   |
| MYC Gain & PTEN Homozygous & ETV1 Split    | 29         | 25                | 6.017       | 0.0033   |
| MYC Gain & PTEN Homozygous & NMYC Gain & 2 Edel | 29   | 25                | 6.017       | 0.0033   |
| MYC Gain & PTEN Homozygous & NMYC Gain & ETV1 Split | 29   | 25                | 6.017       | 0.0033   |
Combinations of FISH parameters in this study were selected that were statistically significant in predicting PCa outcome (progressive vs non-progressive), with the highest performance observed in 4–5 parameter combinations. If used in a multicolour FISH assay, these combinations would require 4–6 FISH probes – a level of multiplexing that is can be achieved with automated imaging systems [32].

Current clinical management and risk stratification of localised prostate cancer for enrolment into AS is based upon several clinical parameters including tumour stage, tumour grade as measured by the Gleason score, and the level of PSA assessed at the time of diagnosis [33]. Although these tools undoubtedly have predictive value, detecting progressive disease in a patient considered or selected for AS remains a challenge. It has been shown that many clinically low-risk prostate cancer patients are upgraded to a more aggressive disease at prostatectomy [34, 35]. According to recent estimates, approximately one-third of the patients are reclassified or upgraded as having a higher risk for progression during AS based on annual surveillance biopsy results [36, 37]. On the other hand, there remains a considerable discrepancy in current AS selection criteria, with a notion that some of the criteria may be too strict, thus excluding some patients in whom expectant management would be appropriate and safe [34, 38]. Therefore, it is important to determine whether genomic tissue biomarkers, such as the multicolour FISH panels used in this study, could improve the accuracy of risk stratification when used in combination with the standard of practice clinical parameters for enrolment into the AS. In the logistic regression that combined clinical risk stratification parameters (NCCN Risk Groups) with FISH, FISH parameter combinations were complimentary to clinical parameters and contributed significantly to the prediction of PCa outcome (progressive vs non-progressive). The combination of clinical parameters and FISH outperformed clinical parameters or FISH alone, with a maximum odd ratio of 7.0 achieved in the final model, as compared to 6.2 for the FISH parameters alone. Importantly, multicolour FISH appeared to add most value to risk stratification in the Intermediate risk group, a group of patients that could benefit from improved selection criteria for AS to reduce overtreatment without compromising survival [39]. Although the specimen set tested in this study is relatively small, an encouraging odds ratios of up to 16.5 were achieved in this group. It appears therefore plausible that utilizing multicolour FISH biomarkers could add value if incorporated into the clinical decision making process.

The limitation of this study is in distinguishing patients with the true rapid progression of the disease vs those with aggressive cancer missed on the initial biopsy due to the sampling error. The latter is especially relevant to the studies on archived specimens, approximately half of which have been collected under the original sextant biopsy protocol. However, one of the advantages of FISH is that it allows assessment of genomic biomarkers in the context of the tumour heterogeneity. In our earlier studies, we demonstrated that cytogenetic abnormalities could be observed by FISH within regions of benign histology extending beyond histologically evident tumour margin, indicating a field cancerisation effect in prostate cancer [40]. This characteristic may be beneficial to reduce sampling error and consequently the risk of missing a higher-grade cancer on initial biopsy prior to enrolment in AS, and would need to be addressed in the future studies. Evaluation of the biomarker combinations presented here warrants an additional study to validate their prognostic utility.

Conclusions

Combinations of FISH parameters capable of discriminating progressive from non-progressive disease were selected based on ROC curve analysis. Combination of clinical parameters with FISH demonstrated improved performance when compared to clinical parameters or to FISH alone. Additionally, FISH proved complimentary to clinical parameters (NCCN Risk Groups) in the final model, demonstrating the potential utility of multicolour FISH panels as an auxiliary tool for PCa risk stratification. Further studies with larger cohorts are planned to confirm these findings.

Additional files

Additional file 1: Summary of Patient Information and FISH. (DOCX 15 kb)

Additional file 2: Correlation Analysis Between FISH Biomarkers and Clinical Parameters. (DOCX 23 kb)

Abbreviations

AS: Active surveillance; AUC: Area Under the Curve; CEP: Chromosome Enumerator Probe; DFI: Distance From Ideal; FFPE: Formalin Fixed Paraffin Embedded; FISH: Fluorescence in situ hybridisation; LSI: Locus Specific Identifier; NCCN: National Comprehensive Cancer Network; PCa: Prostate Cancer; PSA: Prostate-specific antigen; ROC: Receiver Operating Characteristic curve; RP: Radical prostatectomy; WW: Watchful waiting

Acknowledgements

We thank John Schulz and Mona Legator (Abbott Molecular R&D) for designing and manufacturing FISH probes for this study. We also thank Frank Policht (Abbott Molecular R&D) for taking FISH images for this manuscript. We gratefully acknowledge Dr. Klara Abravaya, Sr. Director of Abbott Molecular R&D, for sponsoring this study and for the review of this manuscript.

Funding

The study was funded by Abbott Molecular, Inc. The employees of Abbott Molecular, Inc., contributed to the study design, executed specimen testing and analysis in the Abbott laboratory, collected the data, and transferred the data to KPNC. Data analysis and manuscript preparation was conducted collaboratively, by researchers from participating institutions. KPNC.
investigators were responsible for the final data presentation in the manuscript, data interpretation, clinical opinion, and final manuscript review.

Availability of data and materials
The summary of clinical and Fluorescence In Situ Hybridization parameters for the cohort on study is provided as a supporting file for the manuscript. The line listings for the data generated and analysed in this study are available from the authors KA and SV in a de-identified format to bona fide researchers at request, per IRB approval, with permission of KPNC and Abbott Molecular, Inc.

Authors’ contributions
KP and SKV conceived the study and the study design, provided guidance on data analysis. SKV provided clinical opinion. KP coordinated the study and prepared the manuscript. SKV, CPQ, ADL, and JS created the algorithm to electronically identify patients of interest. Once identified, they reviewed the pathology reports to confirm eligibility and develop the protocol for pathology sample selection. SKV/ADL and JS acquired all pathology samples of interest based on inclusion criteria and shipped to for sample testing. Additionally, SKV, ADL and JS obtained all clinical data relevant to the aims of this project. AK analysed the histological sample and performed data collection and data analysis, YZ coordinated study initiation, analysed the histological samples, performed data analysis. BB and SS conducted testing and analysis of the samples in the laboratory, as well as data entry and data verification. SS coordinated laboratory data collection. HF, JD and CPQ performed statistical analysis. HF and JD drafted the statistical section. ADL contributed to manuscript preparation, including data presentation. LB collected and supplied specimens and clinical information for the feasibility study, contributed to the design, review and analysis of the feasibility experiments, as well as data presentation in the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The work presented in this manuscript has been approved by the Kaiser Permanente Northern California (KPNC) Institutional Review Board (IRB), Oakland, CA, USA, (study reference number 14-1779-H). The Institutional Review Board (IRB) of the Rush University Medical Center, Chicago, IL, USA, reference number L06052503, waived the requirement for informed consent for the research use of archived RP cases from patients with prostate adenocarcinoma cases provided by Rush University Medical Center.

Consent for publication
Not applicable.

Competing interests
KP, AK, YZ, BB, SS, JD and HF are employees of Abbott Molecular, Inc. Authors KP and YZ have filed a pending patent application related to the subject matter of this article. The patent application has been assigned to Abbott Molecular Inc. SV, ADL, and JS received research support for this manuscript, data interpretation, clinical opinion, and final manuscript review.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Abbott Molecular, Inc., 1300 East Touhy Avenue, Des Plaines, IL 60018, USA.
2Rush University Medical Center, Chicago, IL, USA.
3Kaiser Permanente Division of Research, Oakland, CA, USA.

Received: 3 July 2017 Accepted: 13 December 2017
Published online: 02 January 2018

References
1. Siegel R, Miller K, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67:7–30.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. Accessed from: http://gco.iarc.fr/today/home, Accessed 22 Dec 2017.
3. Jaiswal S, Sarmad R, Arora S, Dasaraju R, Sarmad K. Prostate cancer for the internist. N Am J Med Sci. 2015;7:429–35.
4. Toosijian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016;13:205–15.
5. Loeb S, Bjurlin M, Nicholson J, Tammela TL, Penson D, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046–55.
6. Brunsma SM, Bangna CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016;13:151–67.
7. Loos A, Hajjar I, Loeb S, Murphy KN, Epstein J, Klotz L. Active surveillance patient selection. Curr Opin Urol. 2013;23:239–44.
8. Gaudreau PO, Stagg J, Souléilles D, Saad F. The present and future of biomarkers in prostate cancer: proteomics, genomics, and immunology advancements. Biomark Cancer. 2016;8(Suppl 2):15–33.
9. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Akbari A, Beltran H, Movassat A, Golard R, Carreira S, Eble JE, Duhamel M, Tellier ML, Amin MB, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijal J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solt D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:493–503.
10. Mateo J, Carreira S, Sandhu S, Miranda S, Al-Dabbas M, Saghizadeh A, Heng K, Hidalgo M, Heidenreich A, Hussain T, Lauriac V, Reis P, Martini F, Linner P, Battaglia F, Serralta A, Schwartz R, Schäffer AA, Paris PL, Ried T. Single-cell genetic analysis reveals clono-pathologic variables and biomarkers for risk stratification. Nat Rev Urol. 2015;12:7619–26.
11. Klotz L. Active surveillance: patient selection. Curr Opin Urol. 2013;23:239–44.
12. Boyd LM, Xiao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012;9:652–64.
13. Shoaq J, Barbierie CE. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 2016;18:543–8.
14. Akakor DV, Loeb S, Getzenberg RH, Pantin AW. Biomarkers for prostate cancer. Annu Rev Med. 2009;60:139–51.
15. Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sawyers C, Arbuck S, Kocak C, Collins R, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knauf KF, Fingel FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-repair defects and Olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.
16. Nelson WG, De Marzo AM, Isaacs W. Mechanisms of disease. Prostate cancer. N Engl J Med. 2003;349:366–81.
17. Klotz L, Buchbinder RN, Berwick DM, Fletcher C, Nelson J, de Bono J. Active surveillance for prostate cancer: a systematic review of clinico-pathologic variables and biomarkers for risk stratification. Eur Urol. 2015;67:7619–26.
18. Boyd LM, Xiao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol. 2012;9:652–64.
19. Shoaq J, Barbierie CE. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 2016;18:543–8.
20. Makarov DV, Loeb S, Getzenberg RH, Pantin AW. Biomarkers for prostate cancer. Annu Rev Med. 2009;60:139–51.
21. Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sawyers C, Arbuck S, Kocak C, Collins R, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knauf KF, Fingel FY, Chinnaiyan AM, Hall E, de Bono JS. DNA-repair defects and Olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–708.
insights into clonal development of prostate cancers and indicates loss of PTEN as a marker of poor prognosis. Am J Pathol. 2014;184:2671–86.

23. Attard G, Clark J, Ambrosine I, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Borro JS, Scardino P, Cuzick J, Cooper CS. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008;27:253–63.

24. Metz CE. Receiver operating characteristic analysis: a tool for the quantitative evaluation of observer performance and imaging systems. J Am Coll Radiol. 2006;3:413–22.

25. The National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Prostate cancer. v2. 2017.

26. Miller GJ, Torkko KC. Natural history of prostate cancer - epidemiologic considerations. Epidemiol Rev. 2001;23:14–8.

27. Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer. 2015;137:1749–57.

28. Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Elstrathion J, Hyatt AS, Graham PL, Trinh QD, Hu J, Nguyen PL. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Cancer Netw. 2015;13:61–8.

29. Van Stedum S, King W. Basic FISH techniques and troubleshooting. Methods Mol Biol. 2002;204:51–63.

30. Levsky JM, Singer RH. Fluorescence in situ hybridization: past, present and future. J Cell Sci. 2003;116:833–8.

31. Zhao J. Evaluation of the Vysis IntelliFISH hybridization buffer and Vysis IntelliFISH universal FFPE pretreatment and wash kit in FISH assays. N A J Med Sci. 2017;10:5–7.

32. Cellmer M, Feuerbacher I, Krause A. Optical filters and light sources for FISH. In: Liehr T, editor. Fluorescence in situ hybridization (FISH) - Application Guide. Springer protocols handbooks. New York: Springer-Verlag Berlin Heidelberg; 2017. p. 27–42.

33. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445–51.

34. Kim JH, Hoon SK. Potential utility of novel biomarkers in active surveillance of low-risk prostate cancer. Biomed Res Int. 2015;2015:475920.

35. Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, Oriol PF, Sweeney CJ, Trinh QD, Nguyen PL. Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol. 2015;194:393–9.

36. Bul M, van den Bergh RC, Zhu X, Rannikko A, Vasanainen H, Bangma CH, Schröder FH, Roobol MJ. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110:1672–7.

37. Tossoin JJ, Trock BJ, Landis P, Peng Z, Epstein JJ, Partin AW, Walsh PC, Carter HB. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol. 2011;29:2185–90.

38. Elamin S, Bhatt NR, Davis NF, Sweeney P. Validation of selection criteria for active surveillance in prostate cancer. J Clin Diagn Res. 2016;10:PC01–3.

39. Musunuru HB, Yamamoto T, Klotz L, Ghaniem G, Mamedov A, Sethukavalan P, Jethava V, Jain S, Zhang L, Vesprini D, Loblaw A. Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience. J Urol. 2016;196:1651–8.

40. Zhang Y, Perez T, Biordi B, Du J, Liu P, Escarzaga D, Coon JS, Morrison LE, Pestova K. Identification of FISH biomarkers to detect chromosome abnormalities associated with prostate adenocarcinoma in tumour and field effect environment. BMC Cancer. 2014;14:129.